PPIP5K1 and Hepatic steatosis: Moreover, rodent studies using different classes of IP6K inhibitors have suggested that the inhibition of this pathway has beneficial effects on obesity, insulin resistance, hepatic steatosis, osteoporosis, ischemic/reperfusion injury, chronic kidney diseases, and pneumonia [25,34,49,50,52,53].